News | December 07, 2023
Dr. Reddy's inks pact with Coya Therapeutics for development of sclerosis drug
Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya
Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya
The portfolio includes approximately 45 commercial products, four pipeline products and 40 approved non-marketed products, including a number of generic products focused on women’s health.
Dr.Reddy's will receive U.S. $6 million upfront upon closing followed by U.S. $9 million one year from closing
Dr. Reddy's will present the safety profile of the phase 2 study, and interim data of the phase 3 study, which is expected to complete by 2pt February 2021.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)